Koya Medical, a medical device company focused on vascular health innovation, has completed its HQ relocation from Oakland, California, by opening its new headquarters in the Dallas Design District.

The 35,000-square-foot HQ at 2332 and 2340 Valdina St. will be “the new nerve center” for Koya’s manufacturing and business operations, the company said, The move comes as Koya is scaling rapidly to meet rising demand for its therapies targeting venous and lymphatic diseases.

Koya said that as it shifts its core operations to Dallas, it will continue to operate its R&D hub in Silicon Valley.

Lured by Dallas’ ‘talent, infrastructure, and healthcare ecosystem’

“Opening our Dallas headquarters is a defining moment for Koya,” Founder and CEO Andy Doraiswamy, said in a statement. “This move enhances our ability to deliver transformative solutions that empower people living with vascular conditions. Dallas offers the talent, infrastructure, and healthcare ecosystem we need to continue to innovate and grow.”

Also easing Koya’s relocation to Dallas is a grant from the city of Dallas of up to $350,000 to support the HQ move, as the Dallas Business Journal reported in August 2024. According to the DBJ, Koya plans to invest around $1.7 million in its leased Dallas home base by the end of 2028 while creating as many as 200-plus jobs.

Flagship solution is a non-pneumatic wearable compression treatment

Koya was founded in 2018 after Doraiswamy witnessed a family member struggling with mobility and declining quality of life due to lymphedema following cancer treatment. The company has a goal to elevate care for millions of people living with similar venous and lymphatic conditions.

Its flagship device, an FDA-cleared solution called Dayspring, is “the first non-pneumatic wearable compression treatment for chronic edema,” the company said. By combining mobility, adherence, and clinical outcomes in a user-friendly design, Koya described Dayspring as an advance over legacy pneumatic compression devices—and an advance of “what’s possible in home-based treatment.”

Koya noted that 35 million Americans live with venous and lymphatic conditions including lymphedema, chronic venous insufficiency, and deep vein thrombosis. These diseases significantly impact mobility, comfort, and quality of life, and can lead to serious complications, the company added.

Koya says its expanding pipeline “is redefining comprehensive vascular care—from at-home management to advanced hospital interventions.”

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.